Abstract
Vitamins are prominent among natural or endogenous compounds that are considered to be beneficial for both prevention and therapy of various human ailments. The vitamin E group of compounds composed of tocopherol and tocotrienol isoforms, has been subsequently proven to have health benefits including antioxidant and related protective properties. However, individual isoforms exhibit a wide-range of antioxidant potencies. Tocotrienol (T3) displays powerful anticancer activity that is often not exhibited by tocopherols, by modulating multiple intracellular signaling pathways associated with tumor cell proliferation and survival. The anticancer effect of T3 remains not fully understood but generally is mediated independently of its antioxidant activity. Further we have synthesized a new redox-inactive analogue of T3, 6-O-carboxypropyl-α-tocotrienol (T3E) showing considerable promise for stronger anticancer potency than its mother compound. In this mini-review, we particularly focus upon the anticancer action of the above active components of vitamin E and describe current research on the anticancer effects of T3 irrespective of antioxidant activity.
Keywords: Redox-inactive analogue, Tocotrienol, Anticancer activity, Non-antioxidant
Anti-Cancer Agents in Medicinal Chemistry
Title:Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Volume: 13 Issue: 3
Author(s): Tomohiro Yano, Ayami Sato, Miki Sekine, Nantiga Virgona and Masako Ota
Affiliation:
Keywords: Redox-inactive analogue, Tocotrienol, Anticancer activity, Non-antioxidant
Abstract: Vitamins are prominent among natural or endogenous compounds that are considered to be beneficial for both prevention and therapy of various human ailments. The vitamin E group of compounds composed of tocopherol and tocotrienol isoforms, has been subsequently proven to have health benefits including antioxidant and related protective properties. However, individual isoforms exhibit a wide-range of antioxidant potencies. Tocotrienol (T3) displays powerful anticancer activity that is often not exhibited by tocopherols, by modulating multiple intracellular signaling pathways associated with tumor cell proliferation and survival. The anticancer effect of T3 remains not fully understood but generally is mediated independently of its antioxidant activity. Further we have synthesized a new redox-inactive analogue of T3, 6-O-carboxypropyl-α-tocotrienol (T3E) showing considerable promise for stronger anticancer potency than its mother compound. In this mini-review, we particularly focus upon the anticancer action of the above active components of vitamin E and describe current research on the anticancer effects of T3 irrespective of antioxidant activity.
Export Options
About this article
Cite this article as:
Yano Tomohiro, Sato Ayami, Sekine Miki, Virgona Nantiga and Ota Masako, Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1871520611313030012
DOI https://dx.doi.org/10.2174/1871520611313030012 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Physico-Chemical Properties Mediating Reproductive and Developmental Toxicity of Engineered Nanomaterials
Current Medicinal Chemistry Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Current Drug Targets Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides
Current Pharmaceutical Design Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Regulatory Role of the α7nAChR in Cancer
Current Drug Targets TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews